Beigene Ltd
HKEX:6160
Beigene Ltd
Revenue
Beigene Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beigene Ltd
HKEX:6160
|
Revenue
¥17.4B
|
CAGR 3-Years
102%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Revenue
¥9.4B
|
CAGR 3-Years
30%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Revenue
¥2.1B
|
CAGR 3-Years
111%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Revenue
¥2.2B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Revenue
¥3B
|
CAGR 3-Years
28%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Revenue
¥1.9B
|
CAGR 3-Years
291%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
Glance View
BeiGene Ltd., a biopharmaceutical company with origins in Beijing, stands as a prominent player in the global fight against cancer. Founded in 2010, BeiGene has strategically positioned itself as an innovator in the field of oncology, focusing on molecularly targeted and immuno-oncology drug candidates. The company’s journey began with the vision to challenge the conventional barriers to cancer treatment, particularly in emerging markets where access to advanced therapeutics was limited. Its pipeline, robust with both internally developed and in-licensed candidates, reflects an ambitious approach to tackling various forms of cancer, including but not limited to hematological malignancies and solid tumors. The company generates revenue by developing, manufacturing, and commercializing innovative cancer therapies. BeiGene's business model is multifaceted; it involves in-house development and collaborations with international pharmaceutical giants. A significant portion of its revenue is derived from strategic partnerships, such as co-development and commercialization agreements, which allow the company to expand its market reach. Moreover, BeiGene invests heavily in research and development, which not only drives the discovery of new therapies but also strengthens its competitive edge in the pharmaceutical landscape. By balancing scientific advancement with keen market strategies, BeiGene aims to bridge the gap in global cancer care, aspiring to make life-saving treatments accessible to more patients across diverse geographies.
See Also
What is Beigene Ltd's Revenue?
Revenue
17.4B
CNY
Based on the financial report for Dec 31, 2023, Beigene Ltd's Revenue amounts to 17.4B CNY.
What is Beigene Ltd's Revenue growth rate?
Revenue CAGR 5Y
68%
Over the last year, the Revenue growth was 82%. The average annual Revenue growth rates for Beigene Ltd have been 102% over the past three years , 68% over the past five years .
You don't have any saved screeners yet